Samuel Agresta
Keine laufenden Positionen mehr
Vermögen: 1 $ am 31.01.2024
Profil
Samuel Agresta worked as a Director at Infinity Pharmaceuticals, Inc. from 2019 to 2023, as an Associate Medical Director at H.
Lee Moffitt Cancer Center & Research Institute, Inc. from 2004 to 2010, as the Head-Clinical Development at Genentech, Inc. from 2007 to 2010, as the Vice President-Clinical Development at Agios Pharmaceuticals, Inc. from 2011 to 2018, as the Head-Clinical Development at Merrimack Pharmaceuticals, Inc. from 2010 to 2011, and as the Chief Medical Officer at Foghorn Therapeutics, Inc. from 2019 to 2023.
Agresta received a graduate degree from the University of South Florida, a doctorate degree from Tulane University School of Medicine, and a graduate degree from Tulane University School of Public Health & Tropical Medicine.
He also received an undergraduate degree from Georgetown University in 1994.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.05.2023 | 10 593 ( 0,01% ) | 1 $ | 31.01.2024 |
Ehemalige bekannte Positionen von Samuel Agresta
| Unternehmen | Position | Ende |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 11.09.2023 |
| INFINITY PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 16.10.2019 |
| AGIOS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.08.2018 |
| MERRIMACK PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.12.2011 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01.12.2010 |
Ausbildung von Samuel Agresta
| University of South Florida | Graduate Degree |
| Georgetown University | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
| Tulane University School of Public Health & Tropical Medicine | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
H. Lee Moffitt Cancer Center & Research Institute, Inc.
 H. Lee Moffitt Cancer Center & Research Institute, Inc. Miscellaneous Commercial ServicesCommercial Services H. Lee Moffitt Cancer Center & Research Institute, Inc. provides research & contributions to clinical trials, prevention and cancer control. The firm operates as National Cancer Institute (NCI) Comprehensive Cancer Center. The company was founded by Lee H. Moffitt in 1981 and is headquartered in Tampa, FL. | Commercial Services |
